Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study

Respiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first few months of life; however, this risk rapidly decreases with age. Nirsevimab immunoprophylaxis was approved in the European Union for the prevention of RSV-associated lower respiratory tract disease in i...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Guillermo Ezpeleta, Ana Navascués, Natividad Viguria, Mercedes Herranz-Aguirre, Sergio Enrique Juan Belloc, Juan Gimeno Ballester, Juan Carlos Muruzábal, Manuel García-Cenoz, Camino Trobajo-Sanmartín, Aitziber Echeverria, Iván Martínez-Baz, Noelia Vera-Punzano, Itziar Casado, Héctor López-Mendoza, Carmen Ezpeleta, Jesús Castilla
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2024-04-01
Saila:	Vaccines
Gaiak:	respiratory syncytial virus infants nirsevimab monoclonal antibodies hospitalisation vaccination effectiveness
Sarrera elektronikoa:	https://www.mdpi.com/2076-393X/12/4/383
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!